A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.

NCT05735275 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Or Metastatic Solid Tumor Malignancies

Interventions

DRUG: SHR-A2102

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.